Boehringer Ingelheim Buys Rights to Enleofen’s Fibro-inflammatory Anti-IL-11 Platform

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 1 (Table of Contents)

Published: 14 Jan-2020

DOI: 10.3833/pdr.v2020.i1.2498     ISSN: 1756-7874

Section: Licensing



Continuing to expand its fibrotic disease franchise, Boehringer Ingelheim (BI) has acquired the rights to Enleofen’s preclinical interleukin-11 platform in which the latter is eligible to receive in excess of US$1 B in terms of upfront and additional milestone payments per product...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details